Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Passmore

Showing results (111-120 of 134) with videos related to

Pageof 14
Sort By:
Journal of Alzheimer'S Disease : JAD|December 12, 2017
The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) TrialPatrick G Kehoe, Peter S Blair, Beth Howden, et al.
Trials|July 20, 2016
A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocolCaroline Greenan, Lynn Murphy, Ly-Mee Yu, et al.
Journal of Alzheimer'S Disease : JAD|February 8, 2011
A multi-center study of ACE and the risk of late-onset Alzheimer's diseaseOlivia Belbin, Kristelle Brown, Hui Shi, et al.
Molecular Neurodegeneration|July 30, 2011
Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre case-control studyMinerva M Carrasquillo, Olivia Belbin, Talisha A Hunter, et al.
The Lancet. Neurology|October 23, 2021
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trialPatrick Gavin Kehoe, Nicholas Turner, Beth Howden, et al.
Health Technology Assessment (Winchester, England)|April 11, 2025
Lessons from the PROTECT-CH COVID-19 platform trial in care homesPhilip M Bath, Jonathan Ball, Matthew Boyd, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Brain : a Journal of Neurology|October 23, 2015
Common polygenic variation enhances risk prediction for Alzheimer's diseaseValentina Escott-Price, Rebecca Sims, Christian Bannister, et al.
The New England Journal of Medicine|March 9, 2012
Donepezil and memantine for moderate-to-severe Alzheimer's diseaseRobert Howard, Rupert McShane, James Lindesay, et al.
Trials|July 28, 2009
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones, Bart Sheehan, Patrick Phillips, et al.
Pageof 14

Showing results (111-120 of 134) with videos related to

Sort By:
Pageof 14
Journal of Alzheimer'S Disease : JAD|December 12, 2017
The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) TrialPatrick G Kehoe, Peter S Blair, Beth Howden, et al.
Trials|July 20, 2016
A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocolCaroline Greenan, Lynn Murphy, Ly-Mee Yu, et al.
Journal of Alzheimer'S Disease : JAD|February 8, 2011
A multi-center study of ACE and the risk of late-onset Alzheimer's diseaseOlivia Belbin, Kristelle Brown, Hui Shi, et al.
Molecular Neurodegeneration|July 30, 2011
Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre case-control studyMinerva M Carrasquillo, Olivia Belbin, Talisha A Hunter, et al.
The Lancet. Neurology|October 23, 2021
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trialPatrick Gavin Kehoe, Nicholas Turner, Beth Howden, et al.
Health Technology Assessment (Winchester, England)|April 11, 2025
Lessons from the PROTECT-CH COVID-19 platform trial in care homesPhilip M Bath, Jonathan Ball, Matthew Boyd, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Brain : a Journal of Neurology|October 23, 2015
Common polygenic variation enhances risk prediction for Alzheimer's diseaseValentina Escott-Price, Rebecca Sims, Christian Bannister, et al.
The New England Journal of Medicine|March 9, 2012
Donepezil and memantine for moderate-to-severe Alzheimer's diseaseRobert Howard, Rupert McShane, James Lindesay, et al.
Trials|July 28, 2009
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones, Bart Sheehan, Patrick Phillips, et al.
Pageof 14